MYC protein stability is negatively regulated by BRD4

The protooncogene MYC regulates a variety of cellular processes, including proliferation and metabolism. Maintaining MYC at homeostatic levels is critical to normal cell function; overexpression drives many cancers. MYC stability is regulated through phosphorylation: phosphorylation at Thr58 signals...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 117; no. 24; pp. 13457 - 13467
Main Authors Devaiah, Ballachanda N., Mu, Jie, Akman, Ben, Uppal, Sheetal, Weissman, Jocelyn D., Cheng, Dan, Baranello, Laura, Nie, Zuqin, Levens, David, Singer, Dinah S.
Format Journal Article
LanguageEnglish
Published Washington National Academy of Sciences 16.06.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The protooncogene MYC regulates a variety of cellular processes, including proliferation and metabolism. Maintaining MYC at homeostatic levels is critical to normal cell function; overexpression drives many cancers. MYC stability is regulated through phosphorylation: phosphorylation at Thr58 signals degradation while Ser62 phosphorylation leads to its stabilization and functional activation. The bromodomain protein 4 (BRD4) is a transcriptional and epigenetic regulator with intrinsic kinase and histone acetyltransferase (HAT) activities that activates transcription of key protooncogenes, including MYC. We report that BRD4 phosphorylates MYC at Thr58, leading to MYC ubiquitination and degradation, thereby regulating MYC target genes. Importantly, BRD4 degradation, but not inhibition, results in increased levels of MYC protein. Conversely, MYC inhibits BRD4’s HAT activity, suggesting that MYC regulates its own transcription by limiting BRD4-mediated chromatin remodeling of its locus. The MYC stabilizing kinase, ERK1, regulates MYC levels directly and indirectly by inhibiting BRD4 kinase activity. These findings demonstrate that BRD4 negatively regulates MYC levels, which is counteracted by ERK1 activation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Edited by Robert N. Eisenman, Fred Hutchinson Cancer Research Center, Seattle, WA, and approved April 30, 2020 (received for review November 6, 2019)
Author contributions: B.N.D. and D.S.S. designed research; B.N.D., J.M., B.A., S.U., and J.D.W. performed research; D.C., L.B., and Z.N. contributed new reagents/analytic tools; B.N.D., D.L., and D.S.S. analyzed data; and B.N.D. and D.S.S. wrote the paper.
ISSN:0027-8424
1091-6490
1091-6490
DOI:10.1073/pnas.1919507117